EVOTF News and Press, Evotec Ag Ord From 04/10/23

Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts HAMBURG, GERMANY / ACCESSWIRE / April 10, 2023 / Evotec SE (FFSE:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced an update on the cyber attack that was...

HAMBURG, GERMANY / ACCESSWIRE / April 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and dis...

2023-03-28 13:18:08 ET Evotec SE (EVOTF) Q4 2022 Earnings Conference Call March 27, 2023 8:30 A.M. ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Matthias Ev...

8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC'S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PROD...

22% INCREASE IN GROUP REVENUES; EBITDA EXCLUDING M&A AT € 104.1 M POSITIVE MOMENTUM AND OUTLOOK FOR 2023 DATA-DRIVEN PLATFORMS RESULTING IN LARGEST ALLIANCE IN TARGETED PROTEIN DEGRADATION IN THE INDUSTRY HAMBURG, GERMANY / ACCESSWIRE / March 28, 2023 / Evotec SE (Frank...

GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC'S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PROGRAMMES CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOAL 3 "WORLD TUBERCULOSIS DAY", ...

HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023. The Company is going to hold a conference call to discuss the results as ...

KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / March 16, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE00056...

FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD ® TOULOUSE, FRANCE (EU) FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017 UNSECURED LOAN FACILITY TAILORED TO STRATEGIC PLAN...

EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MULTI-MODALITY DRUG DISCOVERY PROGRAMMES EXTENSION AND EXPANSION THROUGH 2030 TO INCLUDE E...